Cross-border biomarker research of ovarian cancerCrossBiomark (HUSRB/1203/214/091) The project is co-financed by the European Union www.hu-srb-ipa.com.

Slides:



Advertisements
Similar presentations
Audit of Impact of NICE guidelines for Ovarian Cancer Helen Losty Royal United Hospital Bath 17th November 2011.
Advertisements

Medical Statistics Joan Morris Professor of Medical Statistics Goldsmiths Lecture 2014.
1. University of Novi Sad, Institute of Food Technology (FINS) – Lead beneficiary University of Szeged, Faculty of Engineering, Department of Food Engineering.
Assist. Prof. Dr. Memet IŞIK Ataturk University Medical Faculty Department of Family Medicine Class 2:
Yan Guo Assistant Professor Department of Cancer Biology Vanderbilt University USA.
FACT:FACT: Ovarian cancer, the deadliest of the gynecologic cancers… Ovarian cancer, the deadliest of the gynecologic cancers…
Tumor Markers Lecture one By Dr. Reem Sallam. Objectives  To briefly introduce cancers, their incidence, some common terms, and staging system.  To.
Michael Birrer, PI, Director, Gynecologic Medical Oncology, MGH Lari Wenzel, Co-PI, Prof. of Medicine, University of California, Irvine
This project is funded with support from the European Commission " Legal disclaimer: the contents of this material is the sole responsibility of implementing.
First HAYAT Annual Patients Forum – 21 st March 2010 – SAS, Kuwait First HAYAT Annual Patients Forum 21 st March 2010 Al Hashimi II Ballroom – SAS Hotel.
Cross-border network for knowledge transfer and innovative development in wastewater treatment WATERFRIEND HUSRB/1203/221/196 Closing conference – Wastewater.
Bindley Bioscience Center Vision: Nurture interactive communication and interdisciplinary discovery with flexible laboratory project spaces and an open.
Technische Universität München Cancer biomarker discovery by chemical and quantitative proteomics Sebastian Berger, B. Sc., Center of Life and.
Introduction of Cancer Molecular Epidemiology Zuo-Feng Zhang, MD, PhD University of California Los Angeles.
In the name of Allah. Development and psychometric Testing of a new Instrument to Measure Affecting Factors on Women’s Behaviors to Breast Cancer Prevention:
Otis W. Brawley, M.D. Chief Medical and Scientific Officer Executive Vice President American Cancer Society Professor of Hematology, Medical Oncology,
Introduction Statistics  Worldwide  Arab World Noor Halawa Dr. Samar Musmar.
Purposes and uses of cancer registration E.E.U. Akang Department of Pathology University College Hospital Ibadan, Nigeria.
THE GUYANA CANCER REGISTRY PRESENTED BY: Penelope Layne: RN,RM,Dp.OSH, BSC Nursing Mangement REGISTRAR GUYANA CANCER REGISTRY July 2013 PRESENTED BY: Penelope.
Biomedical research methods. What are biomedical research methods? An integrated approach using chemical, mathematical and computer simulations, in vitro.
Enhancing Institutional and Administrative Capacity case: POLAND
By Rachel, Xiao Xia, Helen. Introduction Definition Symptoms Causes Prevention Treatment Prognosis Statistics Conclusion.
Positron Emission Tomography (PET) Scans in Ovarian Cancer Effectiveness of PET Scans and Recommendations for CMS August 20, 2008 Ovarian Cancer National.
Background The 2 week wait referral system was designed to expedite the referral of patients, suspected to have cancer, from Primary to Secondary care.
1. Dr. Adel M. Assiri Faculty of Medicine Department of Biochemistry Umm Al-Qura University.
Racial/Ethnic Disparities in Cancer Incidence, Survival and Treatment Linda C. Harlan, PhD, MPH National Cancer Institute Division of Cancer Control and.
Eleni Galani Medical Oncologist
SYNOPSIS OF THE PROTOCOL Title: Pregnancy Associated Breast Cancer (PABC); Prospective Data Registry in Saudi Arabia Sponsor: Oncology Department, King.
Mandi Murph1, Tamotsu Tanaka1, Jihai Pang2, Edward Felix2, James Thompson3 and Gordon Mills1 1Department of Systems Biology, 2Department of Experimental.
LACREMED Development of an enzymological (laccase-based) remediation product and technology Background: Pesticides and their degradation products frequently.
Role of Biomarkers in Management of Prostate Cancer Dr. Angela Amayo Specialist Pathologist 13 th April 2012.
Cross-border network for knowledge transfer and innovative development in wastewater treatment WATERFRIEND HUSRB/1203/221/196 1st HUSRB Students Meeting.
Clinical Division of Oncology Department of Medicine I Medical University of Vienna, Austria Tumormarkers.
THE SURVEY OF PATIENTS’ PERCEPTION AND UNDERSTANDING OF ORAL ANTICOAGULATION THERAPY Author: Fülöp Zsolt Zoltán, coauthors: Drágus Emőke, Elekes Andrea.
Photo: Trym I. Bergsmo. Best and worst cases Sameline Grimsgaard MD MPH PhD National research center in complementary and alternative medicine; NAFKAM.
CA-125 Cancer Antigen-125 Discovered in l981
SEER Provided Data Mohammad Afnan Baqai 12/3/2009.
Ana-Maria Toma (Gabor), Estera Gabor 6th year – Faculty of Medicine
Data Sources-Cancer Betsy A. Kohler, MPH, CTR Director, Cancer Epidemiology Services New Jersey Department of Health and Senior Services.
بسم الله الرحمن الرحيم. Adult Hodgkin’s Lymphoma in the Eastern Part of Libya Dr. M.Mangoush, R. Nafo, S.Kardah, M.Letaiwish, S.Kardah, F.Bodabous, S.Ebkhatra.
The ERA-NET TRANSCAN-2, in continuity with the preceding ERA-NET TRANSCAN, aims at linking translational cancer research funding programmes in 15 Member.
Cross-border network for knowledge transfer and innovative development in wastewater treatment WATERFRIEND HUSRB/1203/221/196 2nd Training course – Industry.
Full Proposal for the German Cancer Aid Priority Program 'Translational Oncology' (2st call) 2015 Lead Applicants: Prof. Dr. med. Magnus von Knebel Doeberitz.
Clinical Trial Design and other Statistical Issues Mary A. Foulkes, Ph.D. Office of Biostatistics and Epidemiology Vaccines and Related Biological Products.
M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 28 – Consumer and Health Protection.
Biomarkers of ovarian cancer and cysts Reproductive Block 1 Lecture Dr. Usman Ghani.
: 1.Introduction The cold shock “Y-box binding protein-1” (YB-1) has an important role in regulation of cellular proliferation and differentiation. Overexpression.
© 2010 Jones and Bartlett Publishers, LLC. Chapter 12 Clinical Epidemiology.
Evaluation of the Cooling Cubes project Dr. Zoltán Kovács – project manager Szeged
The summary of preventive examinations- cervical cancer Agnieszka Wrzesińska, MD Project entitled „ Equal in health – prevention and early detection of.
RESIDENTIAL MOVEMENT BETWEEN TIME OF CANCER DIAGNOSIS & DEATH Recinda Sherman, MPH, CTR Florida Cancer Data System.
1 Accuracy of Cancer Mortality Measured by Death Certificates Project Two Presentations: –Accuracy of Cancer Mortality measured by Death Certificates:
Odor-based Sensors for Ovarian Cancer Detection
Lecture Fifteen Biomedical Engineering for Global Health.
Design of an Endoscopic Raman Probe for Detection of Ovarian Cancer Elizabeth Kanter Matt Keller Vanderbilt University Advisor: Dr. Anita Mahadevan-Jansen.
RESEARCH & INNOVATION SHOWCASE Dr Lauren Walker MRC Clinical Training Fellow supported by the North West England MRC Fellowship Scheme in Clinical Pharmacology.
Squamous Cell Carcinoma
Clinical Epidemiology
The third Annual Conference On Gynecologic Oncology and Prevention Oncology July 20-21, 2017 Chicago, Illinoid USA PPGYNO1 Poster Title.
OMICS Journals are welcoming Submissions
NCD in Bulgaria Assoc. Prof. Plamen Dimitrov, MD, PhD
Performance Comparison of CA125 and the Combination of the Other Serum Biomarkers for the Early Detection of the Ovarian Cancer Hye-Jeong Song1,3,
הקדמה מודל העבודה המוצג להלן הנו פרי עבודה ממושכת ומשותפת של מט"י נגב מזרחי ופרויקט כמ"מProject wealth   בשתיל. תפיסת עבודה משותפת של הפתרונות המתאימים.
Adult granulosa cell tumor and associated cancers Anna Lund Rasmussen, Finn Lauszus, Anne Hammer PhD Department of Gynecology & Obstetrics Herning Hospital.
Funded by the Erasmus+ Programme of the European Union
Fig. 1. scRNA-seq applications in cancer medicine.
Adnexal masses 5 cm in diameter or greater extirpated during cesarean operation Serenat Eris Yalcin1, Yakup Yalcin2, Mehmet Ozgur Akkurt1, And Yavuz1,
SYNOPSIS OF THE PROTOCOL
Receipt of Adjuvant Endometrial Cancer Treatment According to Race NRG Oncology/Gynecologic Oncology Group (GOG) 210 Study Ashley Felix, PhD, MPH Assistant.
Single-cell analyses to tailor treatments
Presentation transcript:

Cross-border biomarker research of ovarian cancerCrossBiomark (HUSRB/1203/214/091) The project is co-financed by the European Union Start of Project: 1 st February 2013 End of Project: 31 s t July 2014

The project is co-financed by the European Union Project Partners University of Szeged (lead beneficiary) Faculty of Medicine Department of Medical Chemistry Dr. Róbert Berkecz, PhD. Tel: , Dr. Tamás Janáky, PhD., DSc. Tel: , Prof. Dr. Gábor Tóth, PhD., DSc. Tel: , Department of Oncotherapy Prof. Dr. László Thurzó, PhD., DSc. Tel: , University of Novi Sad (project partner) Medical Faculty Oncology Institute of Vojvodina Dr. Aljoša Mandić, PhD. Tel: , a

The project is co-financed by the European Union Project Summary Background Ovarian cancer is the leading cause of death from gynecological malignancies and the fifth major cancer in women in the world. Unfortunately, 70 percent of patients has been diagnosed in late, advanced stage of the disease when the efficacy of the therapy and chance of long-time survival are lower. Early stages of tumors usually can be managed with conventional therapies. Nowadays there are no reliable biomarkers for early diagnosis of the disease. Currently used biomarkers (CA-125 and HE4) are not good enough for accurate detection of tumors. Aims of the project The overall gols of the project is identification of new, sensitive and specific blood biomarkers which potentially indicate the appearance of tumors, therefore would help to detect the disease in its early stages. This would enhance the efficacy of the therapy and inrease the chance for long-time survival. Description of work 1. Collection and statistical evaluation of data on epidemiological background of ovarian cancer in South Great Plain and Vojvodina regions. 2. Collection of blood samples from patients with different stages of ovarian cancer from both regions. 3. Development of a state of the art analytical chemical method (two- dimensional liquid chromatography-mass spectrometry ( 2D-LC-MS)) for qualitative and quantitative determination of glycero-phospholipid profile in blood. 4. Determination phospholipid profile in healthy women, patients with different stages of ovarian cancer and patients with benign adnexal masses. 5. Identification of putative biomarker panel by biostatistic and bioinformatic evaluation of phospholipid profiles and conventional tumormarkers.

The project is co-financed by the European Union This document has been produced with the financial assistance of the European Union. The content of the document is the sole responsibility of Department of Medical Chemistry, Faculty of Medicine at University of Szeged and can under no circumstances be regarded as reflecting the position of the European Union and/ or the Managing Authority. Expected outputs 1.The evaluated statistical data will show the distribution of ovarian cancer regarding the age of females and stages of ovarian cancer, and report the tendency of number newly diagnosed patients during the investigated period in South Great Plain and Vojvodina regions.. 2.A state of the art analytical method (2D-LC-MS/MS) for determination of glycero-phospholipids in blood samples to discover biomarkers for differents diseases.. 3.Identification of putative phospholipid biomarkers hopefully indicate early stage of ovarian cancer and help two monitor the efficiency of anticancer therapy. 4.In scienticic proint of view understanding biochemical processes underlying ovarian cancer would help to develop new medical drug against it. 5.Establishing long-term scientific cooperation between Universities of Szeged and Novi Sad. IPA funding: 161,976 Eur State contribution: 28,584 Eur